ALTME.PA PAR
TME Pharma N.V.
1W: -1.9%
1M: -8.0%
3M: +48.2%
YTD: +26.5%
1Y: +1.0%
3Y: -93.9%
5Y: -99.7%
€0.10 ($0.12)
-0.00 (-0.39%)
Weekly Expected Move ±9.8%
€0
€0
€0
€0
€0
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$19K
+11.8% ▲
5Y CAGR: +162.0%
Gross Profit
-$78K
+38.6% ▲
Operating Income
-$5M
+6.2% ▲
Net Income
-$6M
+15.1% ▲
EPS (Diluted)
$-0.21
+84.3% ▲
EBITDA
-$5M
-3.4% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $35 | $33K | $0 | $17K | $19K |
| YoY Growth | -77.3% | +94185.7% | -100.0% | +0.0% | +11.8% |
| Cost of Revenue | $63K | $66K | $92K | $144K | $78K |
| Gross Profit | -$63K | -$66K | -$92K | -$127K | -$78K |
| Gross Margin | -179900.0% | -199.9% | — | -747.1% | -410.5% |
| R&D Expenses | $4M | $11M | $8M | $3M | $2M |
| SG&A Expenses | $2M | $3M | $2M | $3M | $3M |
| Operating Expenses | $6M | $13M | $12M | $5M | $5M |
| Operating Income | -$6M | -$13M | -$12M | -$6M | -$5M |
| Operating Margin | -16482857.1% | -40203.0% | — | -33082.4% | -27773.7% |
| Interest Expense | $5M | $2M | $3M | $2M | $503K |
| Income Before Tax | -$10M | -$14M | -$15M | -$7M | -$6M |
| Tax Expense | $0 | $1K | $7K | $2K | $0 |
| Net Income | -$10M | -$14M | -$15M | -$7M | -$6M |
| Net Margin | -29728571.4% | -43793.9% | — | -39623.5% | -30115.8% |
| EPS (Diluted) | $-32.16 | $-21.90 | $-12.86 | $-1.34 | $-0.21 |
| EBITDA | -$5M | -$13M | -$12M | -$5M | -$5M |
| Shares Outstanding | 323586 | 659850 | 1M | 5M | 27M |